List of Excipients in Branded Drug FLUPHENAZINE HYDROCHORIDE

« Back to Dashboard

Generic Drugs Containing FLUPHENAZINE HYDROCHORIDE

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	fluphenazine hydrochloride	16571-889	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
Rising Pharma Holdings Inc	fluphenazine hydrochloride	16571-889	HYPROMELLOSE 2910
Rising Pharma Holdings Inc	fluphenazine hydrochloride	16571-889	LACTOSE MONOHYDRATE
Rising Pharma Holdings Inc	fluphenazine hydrochloride	16571-889	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in FLUPHENAZINE HYDROCHORIDE?

# Of NDCs	Excipient
2	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6
2	HYPROMELLOSE 2910

Fluphenazine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Fluphenazine hydrochloride is an off-patent, low-cost phenothiazine antipsychotic with limited branded commercial value but several formulation opportunities. The strongest opportunities are differentiated oral delivery, preservative-controlled liquid products, and lifecycle extensions linked to adherence. The highest-value long-acting opportunity involves fluphenazine decanoate rather than fluphenazine hydrochloride itself. Core tablet products face intense generic competition, low reimbursement leverage, and limited patent protection.

What is the regulatory and commercial status of fluphenazine hydrochloride?

Fluphenazine hydrochloride is a first-generation antipsychotic approved for the management of psychotic disorders, including schizophrenia. It is marketed primarily as an oral tablet and oral liquid in generic form. Fluphenazine decanoate is the long-acting injectable ester used for depot treatment and should be analyzed as a separate active pharmaceutical ingredient and formulation platform.

Attribute	Fluphenazine hydrochloride
Therapeutic class	Phenothiazine antipsychotic
Primary dosage forms	Tablets, oral concentrate or solution
Long-acting form	Fluphenazine decanoate injection
Regulatory pathway for new generic	ANDA under Section 505(j)
Reference product status	Legacy product; branded Prolixin products are no longer the primary commercial reference
Patent position	Core compound and conventional dosage-form protection are expired or commercially irrelevant
Orange Book patent risk	No material active patent barrier is generally expected for standard generic tablets
Main commercial constraint	Small market, low price, modest prescribing volume, and competition from newer antipsychotics
Main formulation opportunity	Better tolerability, adherence, dosing convenience, and supply reliability

FDA-approved labeling for fluphenazine products identifies oral tablets and oral concentrate products, while DailyMed records show that inactive ingredients vary by manufacturer and dosage form.[1,2] Product availability can change as manufacturers discontinue or relabel generic presentations.

What patents protect fluphenazine hydrochloride products?

No commercially meaningful blocking patent estate is expected for the fluphenazine hydrochloride molecule, standard oral tablets, or conventional oral liquid formulations. The original compound and basic pharmaceutical uses date to the mid-20th century. Any original composition-of-matter or basic formulation rights have expired.

Orange Book and Paragraph IV exposure

For a conventional fluphenazine hydrochloride tablet, the regulatory strategy is typically an ANDA referencing the relevant FDA-approved product rather than a 505(b)(2) application. A Paragraph IV certification would matter only if an active listed patent appeared in the relevant Orange Book reference-product entry. Standard fluphenazine hydrochloride products do not generally present the type of active Orange Book patent risk associated with newer branded drugs.[3]

The principal regulatory risks are therefore technical and operational:

• Demonstrating pharmaceutical equivalence.
• Establishing bioequivalence for tablets or oral liquids.
• Controlling impurities and degradation products.
• Matching dissolution performance.
• Validating container-closure systems.
• Maintaining reliable supply of low-volume excipients.
• Meeting current cGMP expectations for an older product.

A novel delivery system could qualify for separate intellectual-property protection if it contains a non-obvious excipient combination, release profile, device, manufacturing process, or clinically meaningful use. A simple substitution of lactose for mannitol would rarely support a durable patent position without unexpected technical results.

When does fluphenazine hydrochloride lose exclusivity?

Fluphenazine hydrochloride lost meaningful market exclusivity decades ago. The relevant commercial question is not loss of exclusivity but whether a new product can create value in a mature generic market.

Exclusivity category	Current relevance
Compound patent	Expired
Basic formulation patent	Expired or no longer commercially material
New-drug exclusivity	Expired
Orphan exclusivity	Not generally applicable
Pediatric exclusivity	No material current barrier expected
Standard generic entry	Permitted, subject to FDA approval
New formulation exclusivity	Potentially available if supported by a novel FDA-approved product
505(b)(2) opportunity	Possible for a materially changed dosage form or route

A reformulated product may obtain five years of new chemical entity exclusivity only in limited circumstances and generally would not qualify where the active ingredient has already been approved. A 505(b)(2) product could receive three years of exclusivity for certain new clinical investigations essential to approval, but the exclusivity would not block an ordinary generic of the existing dosage form.[4]

What excipients are used in fluphenazine hydrochloride tablets?

Commercial tablet labels typically use conventional solid oral excipients. Exact compositions depend on the manufacturer and strength. Common excipient classes include fillers, binders, disintegrants, lubricants, glidants, and colorants.

Excipient class	Common candidates	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Tablet mass and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Corn starch, croscarmellose sodium, sodium starch glycolate	Tablet breakup
Lubricant	Magnesium stearate, stearic acid	Ejection and tooling protection
Glidant	Colloidal silicon dioxide	Powder flow
Film former	Hypromellose, polyethylene glycol	Appearance and handling
Colorant	Approved iron oxides or synthetic dyes	Strength identification

FDA’s Inactive Ingredient Database can support initial excipient precedent analysis, but it does not substitute for formulation development or product-specific regulatory assessment.[5] The relevant threshold is the maximum previously approved amount for the same route and dosage form. Excipients outside established precedent may require additional safety justification.

Tablet formulation priorities

A standard immediate-release tablet should prioritize:

1. Low-cost, globally available excipients.
2. Rapid and reproducible disintegration.
3. Low friability at small batch scale.
4. Chemical stability against light and moisture.
5. Compatibility with low-dose drug loading.
6. Distinctive strength identification to reduce medication errors.

Fluphenazine hydrochloride is a potent drug administered at relatively low milligram quantities. Low-dose uniformity is therefore more important than maximizing tablet density. Direct compression may be commercially attractive, but wet granulation can provide better content uniformity when the active is poorly distributed through a high-volume blend.

What excipients are appropriate for fluphenazine hydrochloride oral liquids?

An oral liquid is the most practical dosage-form opportunity for pediatric, geriatric, dysphagic, psychiatric-care, and dose-titration populations. The formulation must address solubility, palatability, microbial control, adsorption, and dose-measurement accuracy.

Potential oral-liquid excipient architecture

Formulation function	Candidate excipients	Key issue
Vehicle	Purified water, glycerin, sorbitol solution	Osmolality and mouthfeel
Solubilization	Ethanol, propylene glycol, surfactant system	Tolerability and pediatric suitability
Buffer	Citrate, phosphate, acetate system	pH stability and preservative performance
Sweetener	Sucrose, sucralose, saccharin sodium	Taste masking and diabetic positioning
Flavor	Mint, fruit, vanilla, or neutral flavor	Phenothiazine bitterness
Preservative	Sodium benzoate, potassium sorbate, parabens	Microbial protection and pH dependence
Chelator	Disodium EDTA	Metal-ion control and preservative support
Suspending agent	Xanthan gum, hydroxypropyl methylcellulose	Only needed for suspension products
Container system	Amber glass or compatible plastic	Light protection and adsorption control

A clear solution is commercially preferable to a suspension if adequate solubility and chemical stability can be achieved. A suspension may reduce solvent use but introduces redispersion, dose uniformity, sedimentation, and shake-well compliance risks.

Taste-masking strategy

Phenothiazines can produce a strong bitter or medicinal taste. Taste masking can combine:

• Reduced free-drug exposure at the tongue surface.
• Sweetener and flavor systems.
• pH optimization.
• Ion-pairing or complexation.
• Polymer-based microspheres.
• Unit-dose oral syringes that reduce contact with the oral cavity.

A heavily alcoholic liquid may be technically simple but commercially weak in institutional, geriatric, pediatric, and substance-use-sensitive settings. A low- or alcohol-free presentation could support a differentiated product claim if stability and solubility are maintained.

What formulations are protected by fluphenazine hydrochloride patents?

No standard fluphenazine hydrochloride excipient combination is generally recognized as carrying a meaningful active patent barrier. New protection would need to focus on a specific technical result.

Potentially protectable formulation concepts include:

• A stable low-alcohol or alcohol-free oral solution.
• A taste-masked liquid with improved dose accuracy.
• A fast-disintegrating tablet with demonstrated improved exposure consistency.
• A multiparticulate formulation that reduces peak-related adverse effects.
• A modified-release formulation that lowers dosing frequency.
• A unit-dose liquid presentation with a validated dosing device.
• A formulation that improves stability under high humidity or elevated temperature.
• A depot system using fluphenazine hydrochloride rather than the decanoate ester, if clinically and technically viable.

Patent claims should be tied to measurable results such as improved dissolution, reduced degradation, reduced precipitation, improved content uniformity, or a defined pharmacokinetic profile. Broad claims covering ordinary excipient substitutions would face substantial invalidity and freedom-to-operate risk.

How does fluphenazine hydrochloride compare with fluphenazine decanoate?

Fluphenazine hydrochloride and fluphenazine decanoate address different commercial needs.

Factor	Fluphenazine hydrochloride	Fluphenazine decanoate
Principal route	Oral	Intramuscular injection
Dosing pattern	Daily or divided dosing	Long-acting depot dosing
Excipient challenge	Solubility, taste, tablet uniformity	Vehicle safety, depot release, injection tolerability
Typical vehicle	Solid oral excipients or aqueous/cosolvent liquid	Oil-based vehicle, commonly sesame oil in legacy products
Adherence benefit	Limited	Higher potential
Manufacturing complexity	Low to moderate	Higher
Regulatory burden	Standard oral bioequivalence	Injectable quality, sterility, particulate, container closure
Commercial differentiation	Taste, dose flexibility, usability	Adherence, clinic workflow, injection convenience
Patent opportunity	Moderate only for novel delivery	Higher technical complexity, but legacy depot products remain mature

The decanoate product creates a separate opportunity for prefilled syringes, lower-volume injection, improved injection-site tolerability, and controlled depot release. Those opportunities do not automatically extend to fluphenazine hydrochloride.

What FDA regulatory pathway applies to new fluphenazine products?

The pathway depends on the degree of formulation and clinical change.

Product concept	Likely pathway
Conventional tablet matching an approved product	ANDA
Conventional oral solution matching an approved product	ANDA, if a suitable reference and equivalence pathway exist
New oral solution with formulation differences	ANDA or 505(b)(2), depending on reference and evidence
Modified-release tablet	505(b)(2) or ANDA if an appropriate reference exists
New delivery device or clinical-use configuration	505(b)(2) may be appropriate
New injectable formulation	ANDA or 505(b)(2), depending on reference product and formulation changes
New indication	505(b)(2) with clinical support
Combination product	505(b)(2) or NDA, depending on the active ingredients and product history

FDA’s ANDA and 505(b)(2) frameworks determine the amount of clinical, pharmaceutical, and comparative evidence required.[4,6] An oral product with no therapeutic differentiation should avoid unnecessary clinical-development cost. A product making an adherence or tolerability claim may require pharmacokinetic or clinical evidence.

Which companies are challenging fluphenazine hydrochloride products?

No high-value, current patent litigation campaign is generally associated with fluphenazine hydrochloride. The commercial field is dominated by generic manufacturers and contract manufacturers rather than branded patent holders.

Potential competitors include:

• Generic tablet suppliers.
• Manufacturers of oral concentrates or solutions.
• Suppliers of fluphenazine decanoate.
• Competing first-generation antipsychotic manufacturers.
• Newer antipsychotic products used as therapeutic substitutes.

The main competitive threat is therapeutic substitution, not Paragraph IV litigation. Prescribers may choose risperidone, olanzapine, quetiapine, aripiprazole, paliperidone, or long-acting injectable alternatives depending on diagnosis, adverse-effect profile, formulary status, and adherence needs.

What generic entry risks exist for fluphenazine hydrochloride?

Generic entry risk is high for conventional tablets and moderate for standard oral liquids. The product has no meaningful compound-patent barrier, and excipient systems are generally commoditized.

Generic launch scenarios

Scenario	Probability profile	Commercial effect
Additional low-cost tablets	High	Price erosion and limited share gains
New oral liquid	Moderate	Niche opportunity in institutions and dysphagia
ODT or orally dispersible product	Moderate	Differentiation if bioequivalence and usability are favorable
Modified-release oral product	Low to moderate	Higher development cost and clinical risk
Preservative-free liquid	Moderate	Potential institutional and specialty value
New fluphenazine hydrochloride injection	Low	Sterility and clinical-development barriers
Improved decanoate delivery system	Low to moderate	Higher value but technically complex

How strong is the patent estate for fluphenazine hydrochloride?

The legacy patent estate is weak for standard products and potentially moderate for a genuinely novel delivery system.

Estate component	Strength
Compound protection	None expected
Standard tablet composition	Weak
Standard oral liquid	Weak to moderate
Taste-masked liquid	Moderate if technically specific
Modified-release product	Moderate to strong if clinically differentiated
Device or packaging	Moderate, usually narrow
Manufacturing process	Moderate if process-specific and difficult to design around
Depot formulation	Moderate to strong depending on release mechanism and clinical data

Patent strength will depend less on the active molecule than on formulation reproducibility, claim breadth, demonstrated performance, and freedom to operate against legacy depot technologies.

What licensing deals could support a fluphenazine opportunity?

A licensing strategy would be more relevant for enabling technology than for fluphenazine intellectual property. Potential targets include:

• Taste-masking platforms.
• Spray-drying or hot-melt extrusion technologies.
• Orally disintegrating tablet platforms.
• Long-acting injectable microspheres.
• Prefilled syringe and injection-device systems.
• Stability-enhancing packaging.
• Contract development and manufacturing organizations with sterile depot capacity.

An acquisition of legacy fluphenazine rights would have limited value unless it includes a differentiated product, established institutional contracts, manufacturing know-how, or an approved delivery system. A technology license should be structured around low fixed fees, milestone payments tied to FDA acceptance, and royalties capped for a low-price generic market.

What revenue exposure and commercial opportunities exist?

Public revenue data for fluphenazine hydrochloride are limited because the product is generic and sales are distributed among manufacturers. The addressable market is likely small relative to modern antipsychotics. Commercial value is concentrated in supply reliability and dosage-form differentiation rather than premium pricing for the molecule.

Highest-value commercial segments

1. Institutional psychiatry and long-term care.
2. Patients with difficulty swallowing tablets.
3. Patients requiring low-dose titration.
4. Health systems facing oral-liquid shortages.
5. Specialty pharmacies supporting compounded or liquid dosing needs.
6. Markets where newer antipsychotics are less affordable.
7. Settings requiring depot adherence strategies.

A successful product would need to win on one or more of four factors: dependable supply, simpler administration, lower total treatment cost, or improved adherence. A conventional tablet alone offers limited strategic upside.

What manufacturing and geographic barriers affect fluphenazine products?

Manufacturing barriers are modest for tablets but increase sharply for liquids and sterile injectables.

Oral tablets

Key controls include:

• Low-dose blend uniformity.
• Moisture and light protection.
• Dissolution consistency.
• Tablet identification.
• Excipient supply security.
• Validation of cleaning and cross-contamination controls.

Oral liquids

Key controls include:

• pH-dependent stability.
• Preservative effectiveness.
• Drug adsorption to container surfaces.
• Dose uniformity during shelf life.
• Container compatibility.
• Accurate oral syringe delivery.
• Microbial control after opening.

Injectables

Key controls include:

• Sterility assurance.
• Endotoxin limits.
• Particulate control.
• Vehicle compatibility.
• Injection-site tolerability.
• Container-closure integrity.
• Depot release reproducibility.

Geographic opportunity is strongest in markets with constrained access to newer antipsychotics, high institutional-care use, or recurring shortages of oral liquids. A global excipient strategy should avoid dependence on a single source of lactose, povidone, polymeric suspending agents, preservatives, or sterile vehicle components. Regional registration requirements may also differ for colors, preservatives, alcohol content, and excipient limits.

Key Takeaways

• Fluphenazine hydrochloride is an off-patent generic drug with weak legacy patent protection.
• Standard tablets offer low development risk but limited commercial upside.
• Oral liquids, alcohol-reduced formulations, taste masking, and dose-delivery systems provide the clearest formulation opportunities.
• A new product must generate measurable technical or clinical differentiation to support meaningful patent claims.
• Fluphenazine decanoate is a separate long-acting injectable opportunity and should not be treated as the same formulation platform.
• Paragraph IV litigation risk is expected to be low; substitution and price erosion are the principal competitive risks.
• Commercial value is most likely in institutional care, dysphagia, titration, supply reliability, and adherence-focused products.
• Manufacturing complexity rises from tablets to liquids to sterile depot injections.

FAQs About Fluphenazine Hydrochloride Formulation and Commercialization

Can fluphenazine hydrochloride be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could use mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and a suitable lubricant. Taste masking and low-dose content uniformity would be the principal development challenges.

Is fluphenazine hydrochloride suitable for a pediatric formulation?

A pediatric-oriented oral liquid could address dose flexibility and swallowing limitations. Development would require careful assessment of alcohol, preservatives, sweeteners, flavorants, excipient exposure, and dose-measurement accuracy.

Can a new fluphenazine hydrochloride formulation receive market exclusivity?

Potentially, but exclusivity would depend on the regulatory pathway and the nature of the innovation. A novel formulation supported by essential clinical investigations may qualify for limited 505(b)(2) exclusivity. Ordinary excipient substitution would not normally create meaningful exclusivity.

What is the best commercial excipient strategy for a fluphenazine oral liquid?

A low-alcohol or alcohol-free, palatable, chemically stable solution with a validated oral syringe is the strongest initial concept. The formulation should minimize solvent burden while maintaining solubility, preservative effectiveness, and shelf-life stability.

Does fluphenazine hydrochloride have biosimilar risk?

No. Fluphenazine hydrochloride is a small-molecule drug, not a biologic. Competition proceeds through generic drug pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Fluphenazine hydrochloride prescribing information. Drugs@FDA.
2. National Library of Medicine. (n.d.). DailyMed: Fluphenazine hydrochloride product labeling.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Food and Drug Administration. (2023). Applications covered by Section 505(b)(2).
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly soluble drug products.